Neoantigen-Based Cancer Vaccines: A Mechanistic and Clinical Review of Personalised Melanoma Imm

02 Apr 20264 min read0 viewsJournal Feed

GIST

Neoantigen-based personalised vaccines for melanoma leverage the high tumor mutational burden and intrinsic immunogenicity of the disease to drive patient-specific T-cell responses. In melanoma, vaccine platform choice shapes the dominant immunological pathway more than an intrinsic, universal mechanism: mRNA vaccines like mRNA-4157 (KEYNOTE-942) favor endogenous antigen expression and MHC class I presentation, typically eliciting robust CD8+ cytotoxic responses; synthetic long peptide (SLP) platforms tend to drive exogenous antigen processing with MHC class II presentation and strong CD4+ T-helper responses.

Nevertheless, cross-presentation can enable CD8+ priming with exogenous peptides under certain conditions. Clinically, mRNA-4157 shows improved recurrence-free survival in the adjuvant setting in melanoma, with efficacy dependent on a “hot” tumour microenvironment; so-called “cold” tumours (e.g., glioblastoma, ovarian cancer) exhibit barriers requiring combination strategies.

The review identifies major bottlenecks to broad adoption: correlating AI-prediction accuracy with outcomes, substantial manufacturing delays (8–16 weeks) with practical risks, and regulatory hurdles for personalised, n-of-1 therapeutics. Ongoing Phase III evaluation of V940-001 (NCT05933577) is anticipated by 2029, reflecting persistent logistical and biological challenges in this field.

Clinical Editorial

Scope and rationale

The article reviews personalised vaccines for melanoma that harness patient-specific tumor mutations (neoantigens) to drive T-cell responses.
Melanoma’s high tumor mutational burden and inherent immunogenicity position it as a leading candidate for neoantigen-based immunotherapy.
Vaccines are considered for potential synergy with immune checkpoint inhibitors by stimulating targeted cytotoxic T-cell activity.

Design and mechanistic themes

The analysis highlights how the vaccine platform shapes the dominant immunological pathway rather than determining it outright.
mRNA-based vaccines tend to promote endogenous antigen production and presentation via MHC class I, which is commonly associated with robust CD8+ T-cell responses.
Synthetic long peptide (SLP) vaccines are more often processed through exogenous pathways favoring MHC class II presentation and CD4+ T-helper responses.
Importantly, exogenous peptide antigens can also be cross-presented on MHC class I under certain conditions, enabling CD8+ T-cell priming despite the exogenous route.

Clinical evidence and context

Trial data point to mRNA-4157 (KEYNOTE-942) showing a notable improvement in recurrence-free survival in the adjuvant setting.
The observed benefit appears to depend on a “hot” tumor microenvironment, with melanoma displaying this characteristic more readily than some other cancers.
In contrast, tumors such as glioblastoma and ovarian cancer, characterized by more immunologically “cold” milieus and barriers (e.g., blood-brain barrier, immune exclusion), may require alternative or additional combination approaches.

Operational and translational hurdles

Validation gaps remain, particularly in aligning artificial intelligence–driven neoantigen predictions with actual clinical outcomes.
Economic and logistical barriers are substantial, including an 8–16 week manufacturing window that can affect patient well-being and timely treatment decisions.
Regulatory navigation for personalized, potentially single-patient (“n-of-1”) therapeutics presents additional challenges.
The field awaits the Phase III readout for V940-001 (NCT05933577), with trial timelines extended to 2029, underscoring the complexity of large-scale validation and recruitment.

Limitations and open questions

The extent to which different platforms can be universally applied across diverse tumor microenvironments remains uncertain.
The review acknowledges uncertainty around how best to integrate neoantigen vaccines with existing immunotherapies in various cancer contexts.

Practical relevance

These findings frame melanoma neoantigen vaccines as a platform whose immunogenic output depends on delivery modality and tumor context.
The ongoing development and regulatory considerations highlight the cautious, incremental path toward broader clinical adoption.

Source Reference

Read the full original publication from the source journal or publisher link below.

Open Original Source More Feed Items

Related by Condition/Drug

Unmasking the targetless illusion: branched clonal evolution of TERT and KIT in acral melanoma revealed by sequential multi-site biopsies- a case report

Infectious Disease • 20 May 2026

Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial

Research Highlights • 16 Apr 2026

Feed Metadata

Source

Frontiers in Immunology